Although imatinib is clearly the treatment of choice for FIP1L1/PDGFRApositive chronic eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment and the possibility of cure in this disorder. To address these questions, 5 patients with FIP1L1/PDGFRA-positive CEL with documented clinical
The tyrosine kinase inhibitor, imatinib mesylate, was originally developed for the treatment of chronic myelogenous leukemia (CML) and has revolutionized the therapy for this disorder. Nevertheless, despite cytogenetic remission and significant reduction of bcr/abl transcripts in response to imatinib mesylate therapy, most studies have failed to demonstrate complete molecular remission in a majority of patients with CML 1 . This is thought to be due to the persistence of a small population of BCR/ABL-positive hematologic progenitors that do not undergo apoptosis in the presence of imatinib [2] [3] [4] .
Although pre-existent bcr-abl kinase mutations in primitive CD34+ cells may explain relapse in some cases 5 , this mechanism does not appear to be widespread 6 .
The FIP1L1/PDGFRA fusion gene is markedly more sensitive to imatinib than BCR/ABL 7 , and patients with this mutation respond dramatically to therapy with clinical, For personal use only. on November 12, 2017. by guest www.bloodjournal.org From hematologic and molecular remission documented in nearly all patients described to date [7] [8] [9] . Furthermore, disease progression while on imatinib appears to be uncommon in patients with FIP1L1/PDGFRA-positive CEL. Although the response to imatinib in these patients is dramatic and appears to be sustained, the optimal dose and duration of imatinib treatment has not been defined. In fact, clinically successful treatment regimens reported in the literature range from 400 mg daily to 100 mg weekly.
In CML, the magnitude of the molecular response is a predictor of relapse and disease progression 10, 11 , and molecular monitoring has been recommended every three months. In part due to the lack of commercially available testing for FIP1L1/PDGFRA, few studies have monitored the molecular response to treatment in FIP1L1/PDGFRApositive CEL except to document initial remission. Finally, although lineage studies suggest the involvement of an early hematopoietic progenitor cell 12 , making the prospect of imatinib cure unlikely in FIP1L1/PDGFRA-positive CEL, this possibility has not been systematically explored.
To address these issues, 5 patients with FIP1L1/PDGFRA-positive CEL with documented clinical, hematologic and molecular remission on an imatinib dose of 400 mg daily and without evidence of cardiac involvement were enrolled in a dose deescalation trial. The imatinib dose was tapered slowly with close followup for evidence of clinical, hematologic and molecular relapse. Two patients with a history of lifethreatening cardiac involvement prior to institution of imatinib therapy were maintained on 300-400 mg of imatinib daily and served as a control population.
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Patients and methods
Patient population. Seven subjects enrolled in a previously described ongoing study of imatinib therapy for hypereosinophilic syndrome 8 were eligible for the present study based on documented presence of the FIP1L1/PDGFRA fusion gene prior to initiation of imatinib therapy and complete clinical, hematologic and molecular remission in response to imatinib. The study was approved by the Institutional Review Board of the National Institutes of Allergy and Infectious Diseases, and informed consent was obtained from all study participants.
Study design. The initial imatinib regimen was selected based on data from phase II studies of chronic myelogenous leukemia (CML), which showed a decreased rate of cytogenetic remission at doses less than 300 mg/day despite decreased circulating blasts 13 . Imatinib therapy was interrupted and restarted at a lower dose for neutropenia (absolute neutrophil count <1000/mm3), thrombocytopenia (platelet count <10,000/mm3 or 50,000/mm3 with clinical evidence of bleeding), transaminase or bilirubin elevation (>5 or >3 times the upper limit of normal, respectively), according to the guidelines proposed for the treatment of CML 14 . Adverse events were graded using the Common Toxicity Criteria of the National Cancer Institute 15 .
All study participants received imatinib mesylate in a single daily oral dose of 300-400 mg for a minimum of 1 year before beginning the dose de-escalation portion of the study. A comprehensive clinical evaluation, including complete blood count (CBC) with differential, routine chemistries, serum IgE, B12 and tryptase levels, electrocardiogram (EKG), echocardiogram, pulmonary function tests (PFTs), and bone marrow aspirate and biopsy, was performed prior to and at 1 month following the 6 initiation of imatinib therapy. CBC and liver function tests were followed weekly for one month after the initiation of therapy, biweekly for two additional months and monthly thereafter. Clinical evaluation, including EKG, echocardiogram, PFTs and molecular testing for the fusion gene, was performed every 3 months.
If molecular testing remained negative (molecular remission) and the subject had no history of endomyocardial fibrosis or other life-threatening complications of HES, the imatinib dose was decreased by 100 mg every three months to a dose of 100 mg daily.
After a minimum of 6 months at 100 mg daily without evidence of molecular relapse, imatinib was discontinued. At this point, the frequency of molecular testing was increased to monthly. In the event of molecular relapse (as defined by two consecutive positive tests), imatinib therapy was reinstituted at 100 mg daily and/or the dose was increased incrementally until molecular remission was documented in two consecutive monthly blood samples or a dose of 600 mg daily was reached.
All laboratory testing reported in this study was performed in the Department of Laboratory Medicine at the NIH Clinical Center, with the exception of serum total tryptase levels, which were measured at the Mayo Medical Labs (Rochester, MN). The normal range for serum tryptase levels (<11.5 ng/ml) was provided by Mayo Medical Labs.
Detection of the FIP1L1-PDGFRA fusion gene. RNA was isolated from peripheral blood mononuclear cells using RNA STAT-60 (Tel-Test, Friendswood, TX) and/or the RNAEasy RNA isolation kit (Qiagen, Valencia, CA). First strand cDNA was synthesized from 2 µg of total RNA using Superscript first-strand synthesis system (Invitrogen) with random hexamer primers. Fusion of FIP1L1 to PDGFRA was detected 7 by nested PCR using primers FIP1L1-F1 (5'-acctggtgctgatctttctgat) and PDGFRA-R1 (5'tgagagcttgtttttcactgga) during the first PCR, and primers FIP1L1-F2 (5'aaagaggatacgaatgggacttg) and PDGFRA-R2 (5'-gggaccggcttaatccatag) for the second PCR. Control RT-PCR for GAPDH was performed using the primers GAPDH-F (5'tggaaatcccatcaccatct) and GAPDH-R (5'-gtcttctgggtggcagtgat).
Statistical analysis. A two-sided Fisher's exact test was used to test for association between de-escalating dose or not and molecular relapse. A P value of < 0.05 was considered statistically significant. None of the patients developed recurrent symptoms and their eosinophil counts, serum B12 and tryptase levels remained suppressed at the point of initial molecular relapse ( Table 2 ). The two patients with cardiac involvement (patients 6 and 7) who remained on 300-400 mg of imatinib daily have remained in clinical, hematologic and complete molecular remission for 51 and 56 months, respectively. Bone marrow examination was performed in 2 patients at the time of molecular relapse and was unchanged from the bone marrow obtained at 1 month post-treatment ( Figure 2 ).
Results
Notably, there was no increase in eosinophilia, cellularity, atypical mast cells or reticulin fibrosis.
Re-initiation of imatinib therapy. Imatinib was restarted at the most recent prerelapse dose in all patients within 2 months of the confirmation of molecular relapse.
Although a second molecular remission was achieved in all patients, two patients (1 and 2) relapsed a second time on the pre-relapse dose. In patient 1, whose initial molecular relapse occurred on 100 mg daily, the fusion gene remained detectable despite an increase in the imatinib dose to 200 mg daily. At this point, imatinib was discontinued briefly when he developed angioedema and abdominal pain that proved to be secondary to lisinopril. Two weeks following imatinib discontinuation, his eosinophil count began to rise peaking at 814/mm3. Imatinib was restarted at 400 mg daily with a decrease in his eosinophil count to his baseline (133/mm3) two weeks later, and a second molecular remission. He remained in molecular remission for 4 months before relapsing again likely due to non-compliance with the drug regimen. With resumption of 400 mg daily, 
Discussion
Although the exquisite sensitivity of FIP1L1/PDGFRA-positive CEL to imatinib mesylate has been well documented in numerous studies, little is known about the durability of the response and the potential for cure with imatinib therapy in this disorder.
Imatinib therapy has been discontinued after molecular remission in patients with CML [16] [17] [18] [19] . Although most patients relapse, some experience durable remissions (9-24 months), and reinitiation of imatinib therapy has been followed by a new molecular response in all cases reported to date. A similar picture has emerged in gastrointestinal stromal tumors (GIST), where 9 of 14 patients developed progressive disease after stopping imatinib therapy with a median progression-free survival of 10 months and no increase in imatinib resistance 20 . A recent report of clinical relapse in 4 FIP1L1/PDGFRA-positive CEL patients who initially responded to imatinib and discontinued therapy for a variety of reasons suggests that relapse occurs with discontinuation of therapy; however, it is unclear whether the patients were in molecular remission at the time of treatment The most appropriate dose of imatinib in FIP1L1/PDGFRA-positive CEL remains controversial, as systematic dose comparison studies have not been performed. In the current study, the dose necessary to suppress the presence of the fusion gene below the level of detection by nested RT-PCR was 100-400 mg daily. Potential reasons for this variability include differences in drug absorption or drug metabolism, non-compliance, differences in disease burden and/or susceptibility of different fusion breakpoints to imatinib. As we did not have access to testing for drug levels during this study, it is not possible to address the first three possibilities directly. It is interesting to note, however, that although two of the subjects (subjects 1 and 5) smoke cigarettes, a known inducer of cytochrome P-450, only one of them (subject 1) required increased dosing. With respect to disease burden, we have previously examined lineage involvement in 5 of the 7 subjects involved in the present study 12 . Although the numbers are small, there was no association between the number of cell lineages involved and either the time to molecular remission or the imatinib maintenance dose (data not shown).
The magnitude of the molecular response has been shown to be a predictor of relapse and disease progression in CML 10, 11 . This is likely to be the case in FIP1L1/PDGFRA-positive CEL; however, the low prevalence of this disorder precludes the large treatment studies needed to address this question. Thus, although quantitative PCR monitoring for FIP1L1/PDGFRA-positive CEL has recently been described 21 , whether this is more useful than the currently available techniques (nested RT-PCR and FISH) in predicting relapse and disease progression is likely to remain unknown.
In summary, we have demonstrated that despite the dramatic clinical, hematologic and molecular response to imatinib in FIP1L1/PDGFRA-positive HES, this therapy appears to suppress rather than eliminate the clonal population. The relatively rapid molecular relapse observed in all patients suggests that interruption of therapy is not indicated in this disorder. Furthermore, although 100 mg daily appears to be sufficient to maintain molecular remission in most patients, some patients appear to require higher doses. Although assessment of the predictive value of molecular remission in preventing disease progression in FIP1L1/PDGFRA-positive CEL is not likely to be possible due to the low prevalence of the disorder, it would seem prudent to follow patients with periodic 
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